4//SEC Filing
Franchini Indrani Lall 4
Accession 0001735276-23-000007
CIK 0001178670other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 5:46 PM ET
Size
14.2 KB
Accession
0001735276-23-000007
Insider Transaction Report
Form 4
Franchini Indrani Lall
EVP, CLO & Secretary
Transactions
- Sale
Common Stock
2023-02-02$226.62/sh−586$132,799→ 3,505 total - Exercise/Conversion
Common Stock
2023-02-01+5,175→ 5,175 total - Sale
Common Stock
2023-02-02$223.97/sh−77$17,246→ 5,098 total - Sale
Common Stock
2023-02-02$225.80/sh−1,007$227,381→ 4,091 total - Sale
Common Stock
2023-02-02$227.38/sh−5$1,137→ 3,500 total - Exercise/Conversion
Restricted Stock Units
2023-02-01−5,175→ 10,350 total→ Common Stock (5,175 underlying)
Footnotes (6)
- [F1]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
- [F6]On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2023 the first third vested and released as reported on this Form 4.
Documents
Issuer
ALNYLAM PHARMACEUTICALS, INC.
CIK 0001178670
Entity typeother
Related Parties
1- filerCIK 0001708764
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 5:46 PM ET
- Size
- 14.2 KB